The FDA issued a Complete Response Letter to Summit Therapeutics for ivonescimab, a lung cancer drug developed by China’s Akeso Biopharma, meaning the application cannot be approved in its current form, according to AP News.
A Complete Response Letter is the FDA’s formal notification that an application cannot proceed without additional information or data. It does not permanently bar a drug from resubmission, but it requires the company to supply additional evidence before approval can proceed.
What the Trial Showed, and What It Didn’t
The HARMONi trial demonstrated tumor control but could not cross the survival threshold the agency required for this application.
The pivotal HARMONi Phase 3 trial tested ivonescimab combined with chemotherapy against chemotherapy alone. Patients enrolled had locally advanced or metastatic non-small-cell lung cancer whose disease had progressed after prior EGFR-targeted therapy.
The combination delayed cancer progression, but the improvement in overall survival did not reach statistical significance, according to Reuters.
Those two outcomes measure different things. Progression-free survival tracks time until disease progression or death, while overall survival measures how long patients live regardless of disease status.
For this application, the FDA determined that a progression-free survival benefit without a statistically significant overall survival improvement did not support a favorable benefit-risk profile, according to AP News.
The Drug and the Companies Behind It
Ivonescimab combines two established cancer-fighting mechanisms in a single engineered molecule.
Akeso Biopharma developed ivonescimab and markets it in China. Summit Therapeutics holds the U.S. rights and filed the American approval application.
The drug is a bispecific antibody, a medicine engineered to act on two targets at once. It blocks PD-1, a checkpoint that tumors exploit to evade immune attack, while also suppressing VEGF, a protein that drives tumor blood-vessel formation. Multiple major pharmaceutical companies are developing therapies on the same PD-1/VEGF approach, according to Bloomberg.
A Test for Chinese Biotech’s Global Ambitions
The outcome raises pointed questions about whether Chinese-originated medicines can consistently meet FDA evidentiary standards.
Ivonescimab had become a prominent example of China’s shift from generic drug manufacturing toward novel medicine discovery, according to Bloomberg. The rejection tests whether that emerging role can translate into durable regulatory success in the United States.
The stated basis for the decision was the application’s clinical evidence, specifically the absence of statistically significant overall survival improvement. Country of origin was not cited as a factor.
Development Continues Elsewhere
The Complete Response Letter covers one indication, leaving ivonescimab’s broader clinical program intact.
The drug remains in clinical development for colorectal, bladder, kidney, and breast cancers. Summit has stated the FDA decision will not change its plans for those programs, according to AP News.
For this application, the FDA determined that progression-free survival alone was insufficient to establish the required benefit. That conclusion reinforces a standard developers and investors must weigh when designing global trials intended to support U.S. approval.






























